Call us +49 (0)761 / 270-51190

The goal of NeuroMac

The main goals of the third funding period are to better understand the molecular mechanisms of myeloid cell
diversity in the CNS and the interactions of microglia and CAMs with neurons, macroglia and vascular cells during brain development, homeostasis and disease. In detail, we want to. In detail, we want to:

  • explore the molecular mechanisms and environmental factors that determine myeloid cell identity in the healthy and diseased CNS (Project area A) (Area A)
  • examine the spatial distribution and local cellular interactions of brain myeloid cells (Project area A) (Area A)
  • identify the cellular mechanisms, metabolic signals and sex-dependent cues for the establishment of contextassociated microglia states and the interactions of myeloid cells with other cells in the affected CNS (Project areas A, B) (Areas A, B)
  • develop strategies for therapeutic targeting of myeloid cells in CNS disorders (Project area B) (Area B)
Research Program

News

Publications

Kim J-S, Trzebanski S, Shin S-H, Schori L, Frumer Friedman GR, Noa Chapal Ilani NC, Kadam A, Vicario R, Aust O, Bugaeva P, Piatek S, Ismajli LK, Hoffmann CJ, Scheller M, Boura-Halfon S, Kaushansky N, Golani O, Solomon A, Liu Z, Amann L, Böhm-Sturm P, Koch SP, Wenger N, Netherlands Brain Bank, Ginhoux F, Prinz M, Avraham R, Harms C, Geissmann F, Müller-Tidow C, Uderhardt S, Milenkovic I, Shlush L, Jung S: Clonal hematopoiesis-associated motoric deficits caused by monocyte-derived microglia accumulating in aging mice . Cell Rep 44(5):115609; doi: 10.1016/j.celrep.2025.115609 (2025).

Sankowski R & Prinz M: A dynamic and multimodal framework to define microglial states. Nat Neurosci; doi: 10.1038/s41593-025-01978-3 (2025).

Frosch M & Prinz M: Niche-specific therapeutic targeting of myeloid cells in the central nervous system . Immunity 58(5):1101-1119; doi: 10.1016/j.immuni.2025.03.016 (2025).

Wang M, Otto C, Fernández Zapata C, Dehlinger A, Gallaccio G, Diekmann LM, Niederschweiberer M, Schindler P, Körtvélyessy P, Kunkel D, Paul F, Ruprecht K, Böttcher C. Comprehensive analysis of B cell repopulation in ocrelizumab-treated patients with multiple sclerosis by mass cytometry and proteomics. iScience. iScience 28(5):112383; doi: 10.1016/j.isci.2025.112383 (2025).

Zähringer A, Morgado I, Erny D, Ingelfinger F, Gawron J, Chatterjee S, Wenger V, Schmidt D, Schwöbel LF, Adams RC, Langenbach M, Hartmann A, Osswald N, Wolf J, Schlunck G, Briquez PS, Grueter K, Ruess DA, Frew I, Burk A-C, Holzmüller V, Grimbacher B, Michonneau D, Andrieux G, Socié G, Kolter J, Börries M, Follo M, Blaeschke F Sevenich L, Prinz M, Zeiser R, Vinnakota JM: AhR activation mitigates graft-versus-host disease of the central nervous system by reducing microglial NF-κB signaling. Blood Adv; doi: 10.1182/bloodadvances.2024015000 (2025).

Schaible P, Henschel J, Erny D: How the gut microbiota impacts neurodegenerative diseases by modulating CNS immune cells.
J Neuroinflammation 22(1):60; doi: 10.1186/s12974-025-03371-0 (2025).